The immune response to a recombinant Lactococcus lactis oral vaccine against foot-and-mouth disease virus in mice

Abstract

Objective Development of an effective mucosal vaccine to induce specific immune responses against Foot-and-mouth disease virus (FMDV). Results For this purpose, the FMDV VP1 gene (SPVP1) was optimized and synthesized based on the codon bias of Lactococcus lactis (L. lactis), and then incorporated in the plasmid pNZ8148. L. lactis NZ9000 containing the pNZ8148-SPVP1 recombinant plasmid was used as an oral delivery vehicle to induce anti-FMDV mucosal and systemic immune responses in mice. After confirmation that the SPVP1 protein was expressed successfully in the recombinant L. latic, the mice were orally challenged with NZ9000-pNZ8148, NZ9000-pNZ8148-SPVP1, phosphate-buffered saline as a mock infection group, or with inactivated vaccine as a positive group. Mice immunized with NZ9000-pNZ8148-SPVP1 produced high levels of mucosal secretory IgA (sIgA), antigenspecific serum IgG, IgA, and neutralizing antibodies, and developed stronger cell-mediated immune reactions and significant T spleen lymphocyte proliferation. Furthermore, the recombinant group generated much higher levels of IFN-c, IL-2, IL-4, IL-5, and IL-10 than the other groups. Conclusions Potent immune responses were successfully elicited in mice with FMDV VP1 delivered through L. lactis.Keywords Lactococcus lactis Á Oral vaccine Á Mucosal immunity Á Foot-and-mouth disease virus Á VP1 protein Xinsheng Liu and Linlin Qi have contributed equally to this study.

Immune Responses to Orally Administered Recombinant Lactococcus lactis Expressing Multi-Epitope Proteins Targeting M Cells of Foot-and-Mouth Disease Virus

“…Through the same method, we obtained the recombinant expression plasmid, pNZ8148-TB1-Co1. In our previous study, were described the preparation process of NZ9000 competent cells [28]. After melting NZ9000 competent cells on ice, 50 µL of recombinant expression plasmids were added followed by mixing with ice-cold competent cells (100 µL), and placed for 5 min on mice.…”

Live Biotherapeutic Lactococcus lactis GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System

“…Therefore, recent studies have introduced recombinant L. lactis as a live vaccine bacterium for delivering antigens to the host immune system [ 18 ]. TRAIL-expressing or IL-12-secreting recombinant L. lactis has been shown to induce the apoptosis of cancer cells or an immune response [ 19 , 20 , 21 , 22 ]. L. lactis itself, however, has not been considered as a live biotherapeutic product, although some studies have revealed that it inhibits the proliferation and induces the apoptosis of cancer cells in stomach and colorectal cancers [ 23 , 24 , 25 , 26 ].…”

Oral Immunization of Mice with Cell Extracts from Recombinant Lactococcus lactis Expressing SARS-CoV-2 Spike Protein

“…Recombinant LAB strains can elicit mucosal immune responses against selected antigens [ 9 ]. In anti-food-and-mouth disease virus (anti-FMDV) research, mice that immunized with that producing FMDV antigen recombinant Lactococcus lactis induced high levels of neutralizing antibodies [ 10 ]. In other research, oral immunization with purified Brachyspira membrane protein B from recombinant E. coli can produce antigen-specific serum IgG and fecal IgA in mice [ 11 ], and it can provide a certain amount of antigen cause immune response.…”